Donald Falgoust, MD
Ophthalmology · Lake Charles, LANPI 1538168323
Payments from drug & device makers
What this record shows
This record is dominated by other: $15,878 of the $19,688 with a category attached, or 80.6%. Olympus America Inc. accounts for 80.6% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $16,756, more than ten times the $247 reported in 2019. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $145.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$16K
- Alcon$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$365
- AbbVie$272
- Bausch & Lomb Americas Inc.$260
- Spineart USA Inc$227
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,76219%
- Gifts$190%
- Entertainment$280%
- Other$15,87881%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 1 | $15,878 |
| Alcon | 32 | $1,336 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 26 | $365 |
| AbbVie(2 entities) | 13 | $272 |
| Bausch & Lomb Americas Inc. | 10 | $260 |
| Spineart USA Inc | 2 | $227 |
| Amgen(2 entities) | 6 | $224 |
| Glaukos Corporation | 3 | $215 |
| Omeros Corporation | 9 | $185 |
| Oyster Point Pharma, Inc. | 5 | $124 |
| Rayner Intraocular Lenses Limited | 6 | $111 |
| Biotissue Holdings Inc. | 5 | $111 |
| Sun Pharmaceutical Industries Inc. | 5 | $103 |
| Tarsus Pharmaceuticals, Inc. | 4 | $95 |
| Sight Sciences, Inc. | 3 | $66 |
| Dompe US, Inc. | 1 | $31 |
| Optos, Inc. | 1 | $28 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$142
- iStent inject W$136
- TEPEZZA$136
- NGENUITY$134
- Wavelight Refractive Suite$134
- Rhopressa$122
- Rocklatan$122
- MIEBO$111
- XIIDRA$111
How this compares
$19,688 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 37 | $52,322 |
| Lotemax SmLoteprednol Etabonate | 171 | $42,413 |
| ProlensaBromfenac Sodium | 76 | $26,519 |
| LumiganBimatoprost | 34 | $22,591 |
| Cyclosporine | 16 | $11,464 |
| Latanoprost | 743 | $10,271 |
| Gatifloxacin | 171 | $7,146 |
| Bromfenac Sodium | 38 | $6,842 |
| Brimonidine Tartrate | 60 | $4,125 |
| Travoprost | 15 | $3,497 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $2,422 |
| Prednisolone Acetate | 79 | $2,311 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 141 | $2,051 |
| Ketorolac Tromethamine | 108 | $1,369 |
| VuityPilocarpine Hcl | 12 | $877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Vuity | $272 | $75,79183 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa | $365 | $68,931247 claims |
| AlconSimbrinza | $1,336 | $2,42212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Lake Charles
- Blake WilliamsonBaton Rouge$443K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Wyche ColemanShreveport$35K
- Peter KastlNew Orleans$32K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
- Arthur DelahoussayeHouma$26K
- Michael RedmondAlexandria$24K
- Eric ReishAlexandria$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.